Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 7/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121008 | 0.97 | DDR1 (0.33) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23121011 | 0.97 | DDR1 (0.33) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL29862847 | 0.95 | DDR1 (0.34) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23136410 | 0.95 | DDR1 (0.34) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23121105 | 0.92 | DDR1 (0.34) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23121102 | 0.92 | DDR1 (0.34) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23121415 | 0.92 | DDR1 (0.34) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23121416 | 0.92 | DDR1 (0.34) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL29862692 | 0.92 | NSD2 (0.33) | DDR1NSD2SLC29A1CNR2CNR1 | |
| SCHEMBL23120978 | 0.91 | CNR2 (0.33) | DDR1NSD2SLC29A1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013756-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-4013756-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | MLLT1, BMI1, DOT1L | DDR1 2446/4885NSD2 102/4885SLC29A1 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.